<DOC>
	<DOCNO>NCT03001219</DOCNO>
	<brief_summary>This Phase 2 double-blind , placebo-controlled , randomize , parallel group , multicenter study evaluate safety efficacy RO7123520 adjunctive therapy participant RA inadequately respond standard-of-care ( methotrexate anti-TNF-alpha therapy ) . Part 1 study evaluate safety . Part 2 evaluate efficacy safety . Part 3 evaluate dose-ranging efficacy . Participants option continue extension period study .</brief_summary>
	<brief_title>A Study RO7123520 Evaluate Safety Efficacy Participants With Moderately To Severely Active Rheumatoid Arthritis ( RA ) Who Are Inadequately Responding Anti-Tumor Necrosis Factor ( TNF ) -Alpha Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis adultonset RA define ACR 2010 criterion , least 6 month screen Moderately severely active RA define least 4/28 tender joint least 4/28 swollen joint , DAS28 â‰¥ 3.2 For Part 2 : Active synovitis dominant hand/wrist determine magnetic resonance imaging Participants must take stable dose antiTNFalpha therapy Participants stable oral glucocorticoid nonsteroidal antiinflammatory drug within 6 week plan randomization Previous , current plan nonTNFalpha therapy treatment RA , tocilizumab , anakinra , abatacept rituximab , etc . Currently receive concomitant treatment hydroxychloroquine , sulfasalazine , leflunomide . Note : enrollment allow appropriate washout period Participants currently infliximab approve biosimilar Parenteral glucocorticoid administration within 6 week prior plan randomization , schedule parenteral administration study Joints inject intraarticular glucocorticoid hyaluronic acid within 6 week prior plan randomization Active inflammatory disease joint related RA systemic autoimmune disease Juvenile idiopathic arthritis juvenile RA and/or RA develop age 16 Active fibromyalgia make appropriate assessment RA disease activity challenge opinion Investigator RA participant functional status class IV accord ACR 1991 criterion Participants severe chronic recurrent viral , bacterial , parasitic , fungal infection History active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) infection Any identify confirm congenital acquire immunodeficiency Abnormal laboratory value liver function test Myocardial infarction within less 6 month prior participation study Severe central peripheral nervous system disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>